09 Nov 2017 Governance

Leukaemia UK is the new name for the ‘Elimination of Leukaemia Fund’

Since November 2017 Leukaemia UK is the new name for the Elimination of Leukaemia Fund.

For the last four decades, Leukaemia UK has been making a difference to those living with blood cancer. We fund emotional support, pay for new hospital facilities, offer critical financial help and fund innovative research into better care and treatments for blood cancers.

We have used this, our 40th year, to review our work and achievements to develop a new strategy and vision for the future.

We want to increase our impact by supporting more families affected by blood cancer and by working with more hospitals around the UK.

Now feels like a good time to change our name from the Elimination of Leukaemia Fund to Leukaemia UK to reflect this ambition. We still hold tight to the founding principles of this charity which are:

  • to improve care and support for people living with blood cancer
  • to fund innovative research to find kinder, more effective ways of treating blood cancer

We have been fortunate to benefit from free consultancy from Frontera, a creative digital agency. The company has helped us develop a new name, logo and brand, at no cost to our supporters.

This new name encompasses our work as a leading blood cancer charity working for a blood cancer cure and improved care.  Our work will remain the same, covering all blood cancers and related disorders.

Our name change won’t affect our charity registration number, office address, bank details and company numbers. For those who donate to us through payroll giving, standing order or direct debit, you won’t need to change anything.

We remain completely reliant on voluntary donations to keep our charity and its important work running. Thank you for your generous support and for being part of our exciting journey.

Find out more about:

 

Related posts

Research Blog: A new target for paediatric AML

29 July 2026

Research Blog: A new target for paediatric AML

In May this year one of our Leukaemia UK funded John Goldman Fellows, Dr Noelia Che, published a new paper along with her colleagues: MCL1 inhibition to enhance the efficacy…

Leukaemia UK appoints Ian McCafferty CBE as their new Chair of Trustees to support new strategy to stop leukaemia devastating lives

7 November 2022

Leukaemia UK appoints Ian McCafferty CBE as their new Chair of Trustees to support new strategy to stop leukaemia devastating lives

Ian McCafferty CBE will take up the role in January 2023, from current Chair of Trustees, Chris Corbin OBE, and will lead the charity as it continues to grow. Chris…

Three leading charities collaborate to fight childhood cancers

2 October 2023

Three leading charities collaborate to fight childhood cancers

New Partnership we3can to fund research into three most common childhood cancers Today (2nd October 2023), three leading cancer charities have launched a new collaboration in order to improve the…

Improving access to life-changing treatment – Leukaemia UK’s role in the approval of Aucatzyl

25 November 2025

Improving access to life-changing treatment – Leukaemia UK’s role in the approval of Aucatzyl

Today, NICE announced its recommendation for Aucatzyl (obecabtagene autoleucel), a CAR-T therapy, to be made available on the NHS for treating adults aged 26 and over with relapsed or refractory…